HR8083119th CongressWALLET

Allowing Greater Access to Safe and Effective Contraception Act

Sponsored By: Representative Hinson

Introduced

Summary

Speeds access to routine oral contraceptives. This bill would require the Health and Human Services Secretary to prioritize FDA supplemental reviews for routine oral contraceptives and waive the associated supplemental application fee.

Show full summary
  • People 18 and older: Would see faster availability of new or updated oral contraceptives because eligible supplemental applications get priority review and the fee is waived.
  • People under 18: Would remain subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act, keeping additional FDA restrictions for minors even after approval.
  • Drug manufacturers: Would receive a waiver of the FDA supplemental application fee for qualifying routine oral contraceptives, lowering a barrier to seeking the change.
  • Federal oversight and policymakers: The Comptroller General must deliver a Government Accountability Office report within 1 year on 15 years of federal funding for contraceptive methods across Medicare, Medicaid, Indian Health Service, the ACA exchanges, federally qualified health centers, title X, TANF, and TRICARE.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

1 provisions identified: 0 benefits, 0 costs, 1 mixed.

Faster access to routine birth control

This bill would require the HHS Secretary to give priority FDA review to supplemental applications for routine oral birth control pills. The rule would not apply to emergency contraceptives or drugs also approved for induced abortion. The FDA would waive the review fee for any supplemental application receiving priority review. If approved, the product could be available without a prescription for people age 18 or older, while people under 18 would still need a prescription. These rules would apply to applications pending at enactment and to ones submitted after enactment.

Free Policy Watch

You just read the policy. Now see what it costs you.

Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.

Pick a topic to get started

Sponsors & CoSponsors

Sponsor

Hinson

IA • R

Cosponsors

  • Miller-Meeks

    IA • R

    Sponsored 3/25/2026

  • Nunn (IA)

    IA • R

    Sponsored 3/25/2026

  • Ciscomani

    AZ • R

    Sponsored 3/25/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in